These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16404151)

  • 1. Sulforaphane inhibits osteoclastogenesis by inhibiting nuclear factor-kappaB.
    Kim SJ; Kang SY; Shin HH; Choi HS
    Mol Cells; 2005 Dec; 20(3):364-70. PubMed ID: 16404151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
    Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
    J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
    Bharti AC; Takada Y; Aggarwal BB
    J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Aggarwal BB
    Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.
    Zhang YH; Heulsmann A; Tondravi MM; Mukherjee A; Abu-Amer Y
    J Biol Chem; 2001 Jan; 276(1):563-8. PubMed ID: 11032840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
    Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
    J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
    Sugatani T; Alvarez UM; Hruska KA
    J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.
    Abu-Amer Y
    J Clin Invest; 2001 Jun; 107(11):1375-85. PubMed ID: 11390419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation.
    Hirayama T; Dai S; Abbas S; Yamanaka Y; Abu-Amer Y
    Arthritis Rheum; 2005 Sep; 52(9):2719-29. PubMed ID: 16142755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling.
    Wei S; Wang MW; Teitelbaum SL; Ross FP
    J Biol Chem; 2002 Feb; 277(8):6622-30. PubMed ID: 11719504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U; Patel K; Rosol TJ; Ostrowski MC
    J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.